Skip to content

Bill Nye the Science Guy is speaking at the 2024 Annual Ataxia Conference! Register now.  LEARN MORE!

Biomarkers for Ataxia and Multiple System Atrophy

Biomarkers for Ataxia and Multiple System Atrophy

The purpose of this study is to identify biomarkers for cerebellar ataxia with unknown etiology and Multiple System Atrophy (MSA). Biomarkers are substances that may diagnose diseases, predict how the disease may change over time and may predict response to therapy. Identifying biomarkers is a first step in developing diagnostic tools and treatments for both diseases.

About the Study

Eligible Ataxia Types
Cerebellar Ataxia of Unknown Etiology (CAUE)

Type of Study
Research Study

Clinical Trial Phase
N/A

Age Range
Adult 18+

Study Start Date
09/26/2019

Estimated Completion Date
06/01/2025

IRB Approval #
00205116

Location

Johns Hopkins
Baltimore, MD 

Contact Information

Ashley Kucharski
akuchar4@jh.edu
410-616-2803

Additional Site

Northwestern University
Evenston, IL

Contact Information

Karen Williams
k-williams8@northwestern.edu
312-503-5645

Additional Site

Columbia University 
New York, NY

Contact Information

Hannah Lee
hhl2124@cumc.columbia.edu
212-305-9718

Additional Site

University of California, Los Angeles (UCLA)
Los Angeles, CA

Contact Information

Darice Wong
DYWong@mednet.ucla.edu
310-825-2320

What does participation in the study entail?

During this study we will obtain plasma through blood draw, urine collection, cerebral spinal fluid (CSF) through a spinal tap procedure and skin samples through a skin biopsy procedure. In addition, we will ask you to complete several different questionnaires, cognitive tests, and neurological exams.

What are the potential benefits for participants?

While there are no direct benefits to you from being in this study, you may help to develop a biomarker for MSA or cerebellar ataxia.

What are the potential risks for participants?

The lumbar puncture may cause discomfort, and there is a small risk of infection, bleeding, and a headache. The blood draw may cause discomfort, bleeding, or bruising where the needle enters the body. If opting for the skin biopsy, there may be discomfort at the places of the biopsy. Lastly, you may get fatigued or bored when we are asking you questions or you are completing questionnaires, but you do not have to answer anything you do not want to answer.

Is there financial compensation?

Yes. Financial compensation varies by study location.

Is there travel reimbursement?

Yes. Reimbursement varies by study location.

Who is eligible?

Individuals over the age of 18 with either Multiple System Atrophy (MSA) or cerebellar ataxia of unknown etiology (CAUE) are eligible for this study. People with CAUE must have had genetic testing that did not show the cause of their ataxia.

View Other Research Opportunities

Print Friendly, PDF & Email

The purpose of this study is to identify biomarkers for cerebellar ataxia with unknown etiology and Multiple System Atrophy (MSA). Biomarkers are substances that may diagnose diseases, predict how the disease may change over time and may predict response to therapy. Identifying biomarkers is a first step in developing diagnostic tools and treatments for both diseases.

About the Study

Eligible Ataxia Types
Cerebellar Ataxia of Unknown Etiology (CAUE)

Type of Study
Research Study

Clinical Trial Phase
N/A

Age Range
Adult 18+

Study Start Date
09/26/2019

Estimated Completion Date
06/01/2025

IRB Approval #
00205116

Location

Johns Hopkins
Baltimore, MD 

Contact Information

Ashley Kucharski
akuchar4@jh.edu
410-616-2803

Additional Site

Northwestern University
Evenston, IL

Contact Information

Karen Williams
k-williams8@northwestern.edu
312-503-5645

Additional Site

Columbia University 
New York, NY

Contact Information

Hannah Lee
hhl2124@cumc.columbia.edu
212-305-9718

Additional Site

University of California, Los Angeles (UCLA)
Los Angeles, CA

Contact Information

Darice Wong
DYWong@mednet.ucla.edu
310-825-2320

What does participation in the study entail?

During this study we will obtain plasma through blood draw, urine collection, cerebral spinal fluid (CSF) through a spinal tap procedure and skin samples through a skin biopsy procedure. In addition, we will ask you to complete several different questionnaires, cognitive tests, and neurological exams.

What are the potential benefits for participants?

While there are no direct benefits to you from being in this study, you may help to develop a biomarker for MSA or cerebellar ataxia.

What are the potential risks for participants?

The lumbar puncture may cause discomfort, and there is a small risk of infection, bleeding, and a headache. The blood draw may cause discomfort, bleeding, or bruising where the needle enters the body. If opting for the skin biopsy, there may be discomfort at the places of the biopsy. Lastly, you may get fatigued or bored when we are asking you questions or you are completing questionnaires, but you do not have to answer anything you do not want to answer.

Is there financial compensation?

Yes. Financial compensation varies by study location.

Is there travel reimbursement?

Yes. Reimbursement varies by study location.

Who is eligible?

Individuals over the age of 18 with either Multiple System Atrophy (MSA) or cerebellar ataxia of unknown etiology (CAUE) are eligible for this study. People with CAUE must have had genetic testing that did not show the cause of their ataxia.

View Other Research Opportunities

Print Friendly, PDF & Email
Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.